Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials
- 3 May 2011
- journal article
- research article
- Published by Elsevier BV in The Journal of Heart and Lung Transplantation
- Vol. 30 (9), 982-989
- https://doi.org/10.1016/j.healun.2011.03.011
Abstract
No abstract availableKeywords
Funding Information
- United Therapeutics Corporation
This publication has 30 references indexed in Scilit:
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2010
- Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEuropean Respiratory Journal, 2009
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- The Ethics of Randomized Clinical Trials in Pulmonary Arterial HypertensionProceedings of the American Thoracic Society, 2008
- Ambrisentan for the Treatment of Pulmonary Arterial HypertensionCirculation, 2008
- Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial HypertensionCirculation, 2008
- Survival in Primary Pulmonary HypertensionCirculation, 2002